Research Analysts Offer Predictions for IOVA FY2027 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Iovance Biotherapeutics in a report released on Wednesday, March 19th. Zacks Research analyst S. Ganoria anticipates that the biotechnology company will earn $0.13 per share for the year. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). The company had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%.

Other analysts also recently issued research reports about the company. Piper Sandler decreased their price target on Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a research note on Friday, February 28th. Chardan Capital decreased their price target on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. Robert W. Baird decreased their target price on Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Friday, February 28th. Finally, The Goldman Sachs Group decreased their target price on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.25.

Iovance Biotherapeutics Stock Performance

IOVA opened at $3.54 on Friday. The company has a market cap of $1.16 billion, a PE ratio of -2.38 and a beta of 0.93. The stock has a 50-day moving average of $5.12 and a 200-day moving average of $7.77. Iovance Biotherapeutics has a 52-week low of $3.42 and a 52-week high of $15.50.

Institutional Trading of Iovance Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC raised its holdings in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. acquired a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. acquired a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $47,000. One68 Global Capital LLC acquired a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $74,000. Finally, Quarry LP acquired a new position in Iovance Biotherapeutics in the 4th quarter valued at approximately $74,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.